We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
Read MoreHide Full Article
Key Takeaways
DNLI stock fell after Takeda ended its DNL593 collaboration, citing strategic priorities, not safety issues.
Denali regains full ownership of DNL593 and plans to advance the therapy independently toward 2026 data.
DNL593 study shows early biomarker gains; Denali now bears full development and commercialization costs.
Shares of Denali Therapeutics Inc. (DNLI - Free Report) were down 6.15% on April 6, after the company announced that partner Takeda (TAK - Free Report) has decided to terminate their collaboration agreement to co-develop and co-commercialize DNL593 (PTV:PGRN) on April 3.
Per DNLI, Takeda’s decision was based on strategic priorities and not on any efficacy or safety issues.
Following the termination of the co-development agreement, Denali will regain full ownership of DNL593 along with its intellectual property.
Denali stock has gained 17.4% year to date compared with the industry’s growth of 0.4%.
Image Source: Zacks Investment Research
More on DNLI’s Frontotemporal Dementia-granulin Candidate
DNL593 is an investigational progranulin replacement therapy designed using Denali’s Protein TransportVehicle (PTV) platform to deliver progranulin across the blood-brain barrier for the treatment of frontotemporal dementia caused by GRN mutations (FTD-GRN).
Denali plans to independently advance DNL593 and post phase I/II study results by the end of 2026.
The ongoing phase I/II study of DNL593 has completed enrollment with 40 participants diagnosed with FTD-GRN, with biomarker data expected later in 2026. Earlier interim results from healthy volunteers showed dose-dependent increases in cerebrospinal fluid progranulin levels, indicating effective brain delivery. The therapy has been generally well tolerated so far, with no major safety concerns reported.
Frontotemporal dementia is the most common form of dementia in individuals under 60. It leads to progressive decline in behavior, personality, and language or motor functions. Mutations in the GRN gene, which encodes the progranulin protein, are among the leading genetic causes of the disease. Currently, there are no approved treatments to halt or slow its progression.
Regaining full control of DNL593 is a strategic positive, as it allows Denali to capture all future value if the therapy succeeds.
However, Takeda’s exit may raise concerns. Even though the decision was not tied to safety or efficacy, the loss of a large pharma partner removes external validation and shared financial burden. Denali will now need to fund late-stage development and potential commercialization on its own, increasing capital requirements.
Denali’s Recent Drug Approval: A Major Boost
Last month, Denali secured a major regulatory win with the FDA approval of lead pipeline candidate tividenofusp alfa-eknm, under the brand name Avlayah, for the treatment of Hunter Syndrome.
The approval marks the company’s first commercial product and a potential inflection point for its long-term growth story.
The FDA granted accelerated approval to Avlayah, marking the first new treatment option in nearly 20 years for patients with Hunter syndrome, a rare lysosomal storage disorder. It is also the first approved therapy in a new class of biologics designed to cross the blood-brain barrier by targeting the transferrin receptor.
While successful commercialization remains key, the approval of Avlayah underscores the potential of Denali’s TransportVehicle platform to address the longstanding challenge of delivering biologic therapies across the blood-brain barrier, with the goal of transforming treatment for a broad range of neurodegenerative diseases, lysosomal storage disorders, and other serious conditions affecting millions worldwide.
Denali boasts a deep pipeline. One promising asset is DNL126, being developed for Sanfilippo syndrome type A, a rare pediatric neurodegenerative disorder. DNLI is also evaluating DNL628 (OTV:MAPT) for Alzheimer’s disease.
Strategic partnerships further strengthen Denali’s development capabilities and help mitigate financial and clinical risk.
Denali is developing other candidates in partnership with Biogen (BIIB - Free Report) and Sanofi (SNY - Free Report) .
DNLI and Biogen continue co-development of BIIB122.
Biogen is leading the global phase IIb LUMA study, evaluating BIIB122's impact on disease progression in early-stage PD. Data is expected in mid-2026.
Denali is conducting the phase IIa BEACON study, specifically enrolling participants with LRRK2-associated PD, to assess how LRRK2 inhibition may impact this disease.
Sanofi is developing eclitasertib for the treatment of moderate-to-severe ulcerative colitis. Data from the phase II study is expected in the first half of the year.
Another promising asset is DNL126, being developed for Sanfilippo syndrome type A, a rare pediatric neurodegenerative disorder. DNLI is also evaluating DNL628 (OTV:MAPT) for Alzheimer’s disease.
The company’s sound cash position is a positive and underscores its ability to fund ongoing programs.
View the Zacks #1 Rank List
Image: Bigstock
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
Key Takeaways
Shares of Denali Therapeutics Inc. (DNLI - Free Report) were down 6.15% on April 6, after the company announced that partner Takeda (TAK - Free Report) has decided to terminate their collaboration agreement to co-develop and co-commercialize DNL593 (PTV:PGRN) on April 3.
Per DNLI, Takeda’s decision was based on strategic priorities and not on any efficacy or safety issues.
Following the termination of the co-development agreement, Denali will regain full ownership of DNL593 along with its intellectual property.
Denali stock has gained 17.4% year to date compared with the industry’s growth of 0.4%.
Image Source: Zacks Investment Research
More on DNLI’s Frontotemporal Dementia-granulin Candidate
DNL593 is an investigational progranulin replacement therapy designed using Denali’s Protein TransportVehicle (PTV) platform to deliver progranulin across the blood-brain barrier for the treatment of frontotemporal dementia caused by GRN mutations (FTD-GRN).
Denali plans to independently advance DNL593 and post phase I/II study results by the end of 2026.
The ongoing phase I/II study of DNL593 has completed enrollment with 40 participants diagnosed with FTD-GRN, with biomarker data expected later in 2026. Earlier interim results from healthy volunteers showed dose-dependent increases in cerebrospinal fluid progranulin levels, indicating effective brain delivery. The therapy has been generally well tolerated so far, with no major safety concerns reported.
Frontotemporal dementia is the most common form of dementia in individuals under 60. It leads to progressive decline in behavior, personality, and language or motor functions. Mutations in the GRN gene, which encodes the progranulin protein, are among the leading genetic causes of the disease. Currently, there are no approved treatments to halt or slow its progression.
Regaining full control of DNL593 is a strategic positive, as it allows Denali to capture all future value if the therapy succeeds.
However, Takeda’s exit may raise concerns. Even though the decision was not tied to safety or efficacy, the loss of a large pharma partner removes external validation and shared financial burden. Denali will now need to fund late-stage development and potential commercialization on its own, increasing capital requirements.
Denali’s Recent Drug Approval: A Major Boost
Last month, Denali secured a major regulatory win with the FDA approval of lead pipeline candidate tividenofusp alfa-eknm, under the brand name Avlayah, for the treatment of Hunter Syndrome.
The approval marks the company’s first commercial product and a potential inflection point for its long-term growth story.
The FDA granted accelerated approval to Avlayah, marking the first new treatment option in nearly 20 years for patients with Hunter syndrome, a rare lysosomal storage disorder. It is also the first approved therapy in a new class of biologics designed to cross the blood-brain barrier by targeting the transferrin receptor.
While successful commercialization remains key, the approval of Avlayah underscores the potential of Denali’s TransportVehicle platform to address the longstanding challenge of delivering biologic therapies across the blood-brain barrier, with the goal of transforming treatment for a broad range of neurodegenerative diseases, lysosomal storage disorders, and other serious conditions affecting millions worldwide.
Denali boasts a deep pipeline. One promising asset is DNL126, being developed for Sanfilippo syndrome type A, a rare pediatric neurodegenerative disorder. DNLI is also evaluating DNL628 (OTV:MAPT) for Alzheimer’s disease.
Strategic partnerships further strengthen Denali’s development capabilities and help mitigate financial and clinical risk.
Denali is developing other candidates in partnership with Biogen (BIIB - Free Report) and Sanofi (SNY - Free Report) .
DNLI and Biogen continue co-development of BIIB122.
Biogen is leading the global phase IIb LUMA study, evaluating BIIB122's impact on disease progression in early-stage PD. Data is expected in mid-2026.
Denali is conducting the phase IIa BEACON study, specifically enrolling participants with LRRK2-associated PD, to assess how LRRK2 inhibition may impact this disease.
Sanofi is developing eclitasertib for the treatment of moderate-to-severe ulcerative colitis. Data from the phase II study is expected in the first half of the year.
Another promising asset is DNL126, being developed for Sanfilippo syndrome type A, a rare pediatric neurodegenerative disorder. DNLI is also evaluating DNL628 (OTV:MAPT) for Alzheimer’s disease.
The company’s sound cash position is a positive and underscores its ability to fund ongoing programs.
DNLI's Zacks Rank
Denali currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.